1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
0.03
D/E ratio less than half the Drug Manufacturers - Specialty & Generic median of 0.12. Benjamin Graham would praise this conservative approach, but check if excess equity dilutes returns.
-1.44
Net cash position versus Drug Manufacturers - Specialty & Generic median net debt of 1.38. Peter Lynch would praise the flexibility but check if overcapitalized versus growth opportunities.
-28.82
Negative coverage while Drug Manufacturers - Specialty & Generic median is 0.00. Seth Klarman would scrutinize operating performance and look for turnaround catalysts.
2.67
Current ratio near Drug Manufacturers - Specialty & Generic median of 2.69. David Dodd would examine if industry-standard liquidity is appropriate given business model.
51.53%
Intangibles exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 7.89%. Michael Burry would check for aggressive accounting and hidden risks.
